Clinical Trials Network: Admin Supplement: Integrating MOUD with BUP in Non-medical Community Settings
临床试验网络:管理补充:在非医疗社区环境中将 MOUD 与 BUP 集成
基本信息
- 批准号:10801347
- 负责人:
- 金额:$ 5.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-06 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAccident and Emergency departmentAddressAfrican American populationBehavioralBlack PopulationsBlack raceBuprenorphineCOVID-19CaringChicagoChurchCitiesClinicClinical Trials NetworkCommunitiesCommunity Health AidesConsolidated Framework for Implementation ResearchCounselingCountyEffectivenessFaithFederally Qualified Health CenterFrightHuman ResourcesIndividualInterviewLegalMeasuresMedicaid eligibilityMedicalModelingNeighborhoodsParticipantPatientsPharmaceutical PreparationsPhasePopulationProviderRandomizedRecoveryResearchServicesSiteSocioeconomic FactorsSpecialistSubstance Use DisorderSystemTelemedicineTrainingTrustVisitWashingtonbarrier to carecollaborative carecommunity engagementcommunity organizationscommunity settingcomparative effectivenesseffectiveness evaluationeffectiveness/implementation trialexperienceimplementation barriersimplementation facilitatorsimprovedmedication compliancemedication for opioid use disorderopioid mortalityopioid overdoseopioid use disorderoutreachoverdose deathpatient retentionpeer recoveryprior authorizationpsychoeducationpsychoeducationalracial disparitysocial stigmatreatment as usual
项目摘要
Abstract
Racial disparities in engagement and retention in treatment with medication treatment for opioid use
disorder (MOUD) are profound and persistent and have devastating consequences. Black/African
American persons have experienced the fastest increases in opioid overdose deaths nationally since
2013 and now have higher rates of overdose deaths than whites. During 2020, the number of Black
persons dying from an opioid overdose increased by 45% compared to the previous year, nearly double
the increase for white overdose deaths. Despite the great need for MOUD, Black/African Americans
are less likely than whites to receive MOUD, especially buprenorphine, and have substantially lower
rates of MOUD treatment retention. Our own and others’ research identify that stigma, medical mistrust,
fear of legal consequences, and bias and misunderstanding about MOUD contribute to underutilization
of MOUD in Black/African American populations. To address these barriers, outreach, engagement,
and reengagement by community-based Peer Recovery Specialists ( trained individuals with shared
lived experience of SUD recovery), providing MOUD in a broader range of settings and by telemedicine,
and a collaborative care model integrating provision of substance use disorder treatment generally or
MOUD with buprenorphine in trusted, community sites, have been found to be feasible and attractive
to Black/African American persons with untreated OUD. We propose a multi-site hybrid implementation-
effectiveness trial to be conducted in Washington, DC, Chicago, and Miami/Dade County to evaluate:
1) implementation of the Integrated Collaborative Community MOUD care model (ICC-MOUD) and
2) the effectiveness of this model for improving 6-month retention in MOUD with buprenorphine among
currently untreated Black/African Americans with OUD compared to Medical Clinic-office-based
MOUD with buprenorphine (MC-MOUD). In ICC-MOUD, community sites serve as “spokes” for
telemedicine provision of MOUD by buprenorphine providers based in a “hub” buprenorphine clinic,
Peer Recovery Specialists will conduct outreach, engagement, and reengagement activities in the
community and serve as facilitators for telemedicine visits at the community site, and a community
health worker trained to serve as a Recovery Guide will provide on-site psychoeducation and behavioral
counseling to promote retention in care, medication adherence, and behavioral change. In MC-MOUD,
participants are referred to and treated entirely in a MOUD clinic/office.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gail D'Onofrio其他文献
Gail D'Onofrio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gail D'Onofrio', 18)}}的其他基金
Yale-METRO Metropolitan Emergency Trial netwoRK to advance patient Outcomes
耶鲁大学-METRO 大都会紧急试验网络可改善患者的治疗效果
- 批准号:
10552382 - 财政年份:2023
- 资助金额:
$ 5.79万 - 项目类别:
Standard versus High Dose ED-Initiated Buprenorphine Induction
标准剂量与高剂量 ED 引发的丁丙诺啡诱导
- 批准号:
10801950 - 财政年份:2023
- 资助金额:
$ 5.79万 - 项目类别:
Clinical Trials Network New England Consortium Node: Admin Supplement CTN0131
临床试验网络新英格兰联盟节点:管理补充 CTN0131
- 批准号:
10655837 - 财政年份:2022
- 资助金额:
$ 5.79万 - 项目类别:
National Institute on Drug Abuse Clinical Trial Network: New England Consortium Node
国家药物滥用研究所临床试验网络:新英格兰联盟节点
- 批准号:
10684501 - 财政年份:2022
- 资助金额:
$ 5.79万 - 项目类别:
Clinical Trials Network New England Consortium Node: Admin Supplement CTN0126
临床试验网络新英格兰联盟节点:管理补充 CTN0126
- 批准号:
10655828 - 财政年份:2022
- 资助金额:
$ 5.79万 - 项目类别:
The National Drug Abuse Clinical Trials Network: New England Consortium Node
国家药物滥用临床试验网络:新英格兰联盟节点
- 批准号:
10450554 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
The National Drug Abuse Clinical Trials Network: New England Consortium Node
国家药物滥用临床试验网络:新英格兰联盟节点
- 批准号:
10442107 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
The National Drug Abuse Clinical Trials Network: New England Consortium Node
国家药物滥用临床试验网络:新英格兰联盟节点
- 批准号:
10451986 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
EMBED: Pragmatic trial of user-centered clinical decision support to implement EMergency department-initiated BuprenorphinE for opioid use Disorder
EMBED:以用户为中心的临床决策支持的实用试验,以实施急诊部门发起的丁丙诺啡E治疗阿片类药物使用障碍
- 批准号:
9928151 - 财政年份:2018
- 资助金额:
$ 5.79万 - 项目类别:
EMBED: Pragmatic trial of user-centered clinical decision support to implement EMergency department-initiated BuprenorphinE for opioid use Disorder
EMBED:以用户为中心的临床决策支持的实用试验,以实施急诊部门发起的丁丙诺啡E治疗阿片类药物使用障碍
- 批准号:
10379284 - 财政年份:2018
- 资助金额:
$ 5.79万 - 项目类别:














{{item.name}}会员




